Lineage Cell Therapeutics
LCTX · NYSE American
$0.9726+$0.0198 (+2.08%)TodayMarket closed ·
Prev close $0.9528
EPS: actual vs estimate
Beat the estimate in 4 of the last 8 quarters, by 77.6% on average
Reported EPS
Estimated EPS
| Quarter | Estimate | Reported | Surprise |
|---|---|---|---|
| Q2 FY26 | -$0.0289 | $0.01 | +134.6% |
| Q1 FY26 | -$0.0204 | -$0.03 | −47.1% |
| Q4 FY25 | -$0.0527 | $0.00 | +100.0% |
| Q3 FY25 | -$0.0262 | -$0.13 | −396.2% |
| Q2 FY25 | -$0.0277 | -$0.07 | −152.7% |
| Q1 FY25 | -$0.0255 | -$0.02 | +21.6% |
| Q4 FY24 | -$0.0087 | -$0.01 | −14.9% |
| Q3 FY24 | -$0.0437 | -$0.02 | +54.2% |
Earnings calls
- LCTX - Earnings call Q2 2026
- Special Call - Lineage Cell Therapeutics, Inc.
- LCTX - Earnings call Q1 2026
- LCTX - Earnings call Q4 2025
- LCTX - Earnings call Q3 2025
- H.C. Wainwright 27th Annual Global Investment Conference
- LCTX - Earnings call Q2 2025
- H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.